HCCS

Across TCGA pan-cancer cohorts, HCCS Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HCCS data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher HCCS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HCCS expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.

LUSC, UCEC, and SKCM are the cancer types where HCCS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.156	0.675	.014	24	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	All	0.186	0.613	.016	6	view →
LIHC	DFS	Median	III,IV	1.000	0.169	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HCCS–LUSC (OS)

Open the LUSC breakdown →